6-异丙基烟醛 | 107756-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-异丙基烟醛
• 英文名称: 6-Isopropyl-3-pyridinecarbaldehyde
• 英文别名: 6-Isopropylnicotinaldehyde；6-propan-2-ylpyridine-3-carbaldehyde
• CAS: 107756-03-6
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: JWIPUXPJHVUROQ-UHFFFAOYSA-N

物化性质

• 沸点：
  246.9±20.0 °C(Predicted)
• 密度：
  1.033±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-异丙基烟醛 在 哌啶 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 吡啶 为溶剂， 生成
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  1-[5-[bis(trimethylsilyl)methyl]-2-propan-2-yl-2H-pyridin-1-yl]-2-methylpropan-1-one 在 ammonium cerium (IV) nitrate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.25h， 以50%的产率得到6-异丙基烟醛
  参考文献：
  名称：

  有机金属试剂向3-Gemins双（甲硅烷基）N-酰基吡啶鎓的区域选择性亲核加成反应

  摘要：

  已经描述了向3-二元双（甲硅烷基）N-酰基吡啶鎓的区域选择性亲核加成。双组分双（硅烷）显示出相反的作用，导致添加不同亲核试剂时具有不同的区域选择性：其空间效应占优势，有利于烷基，乙烯基和芳基有机金属试剂的1,6-加成；其指导作用占优势，有利于减少空间要求较低的炔基格利雅试剂的1,2-加成。

  DOI：

  10.1021/ol500302r

文献信息

• .omega.-(3-pyridyl)alkenamide derivatives and anti-allergenic
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04778796A1

  公开（公告）日：1988-10-18

  Compounds of the formula: ##STR1## wherein X is alkylene or --(CR.sub.6 .dbd.CR.sub.7).sub.r -- wherein R.sub.6 is H, alkyl or phenyl, R.sub.7 is H, alkyl, cyano or phenyl, and r is 1 or 2; A is alkylene or alkylene interrupted by at least one double bond; R.sub.1 is H, halogen, alkyl, alkoxy, alkylthio, cycloalkyloxy, cycloalkylthio, alkoxycarbonyl, carboxy, phenyl, phenoxy, phenylthio, 3-pyridyloxy or 3-pyridylthio; R.sub.2 is H, hydroxy, alkanoyloxy or alkoxycarbonyloxy, or adjacent R.sub.1 and R.sub.2 may combine to form tetramethylene or --CH.sub.2 OCR.sub.8 R.sub.9 O-- (R.sub.8 and R.sub.9 are alkyl); R.sub.3 is H, alkyl or hydroxyalkyl; R.sub.4 is H or alkyl; R.sub.5 is phenyl, heteroaryl or --(CH.sub.2).sub.m --CHR.sub.10 R.sub.11 (R.sub.10 is H or phenyl, R.sub.11 is phenyl or pyridyl and m is 0 to 2); p is 0 or 1; and q is 2 or 3; the phenyl group or moiety being optionally substituted, and a salt thereof, process for the preparation thereof, and pharmaceutical composition containing the same. Said compounds and salts thereof show excellent antiallergic activity mainly through 5-lipoxygenase inhibiting activity, antihistamine activity and/or inhibitory activity against chemical mediator release and useful for treatment of allergic diseases.

  该公式化合物为：##STR1## 其中X为烷基或--(CR.sub.6.dbd.CR.sub.7).sub.r --，其中R.sub.6为H、烷基或苯基，R.sub.7为H、烷基、氰基或苯基，r为1或2；A为烷基或至少有一个双键的烷基；R.sub.1为H、卤素、烷基、烷氧基、烷硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基；R.sub.2为H、羟基、烷酰氧基或烷氧羰酰氧基，或相邻的R.sub.1和R.sub.2可以结合形成四亚甲基或--CH.sub.2 OCR.sub.8 R.sub.9 O--（其中R.sub.8和R.sub.9为烷基）；R.sub.3为H、烷基或羟基烷基；R.sub.4为H或烷基；R.sub.5为苯基、杂环芳基或--(CH.sub.2).sub.m --CHR.sub.10 R.sub.11（其中R.sub.10为H或苯基，R.sub.11为苯基或吡啶基，m为0到2）；p为0或1；q为2或3；苯基或基团可选择性地被取代；以及其盐、制备方法和含有它的药物组成物。所述化合物及其盐主要通过5-脂氧酶抑制活性、抗组胺活性和/或化学介质释放抑制活性表现出优异的抗过敏活性，并用于治疗过敏性疾病。
• VIRAL POLYMERASE INHIBITORS
  申请人：STAMMERS Timothy

  公开号：US20110230465A1

  公开（公告）日：2011-09-22

  Compounds of formula I: wherein X, R 2 , R 3 , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

  式I的化合物：其中X、R2、R3、R5和R6的定义如本文所述，可用作丙型肝炎病毒NS5B聚合酶的抑制剂。
• Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
  申请人：NUEVOLUTION A/S

  公开号：US10683293B2

  公开（公告）日：2020-06-16

  Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

  所公开的是对核受体具有活性的化合物、含有这些化合物的药物组合物以及这些化合物在治疗中的用途。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• [EN] HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] INTERMÉDIAIRE DE COMPOSÉ HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 杂环类化合物、中间体、其制备方法及应用
  申请人：WUHAN LL SCIENCE AND TECH DEVELOPMENT CO LTD

  公开号：WO2020135771A1

  公开（公告）日：2020-07-02

  本发明公开了一种杂环类化合物、中间体、其制备方法及应用。本发明提供了一种如式I所示的杂环类化合物、其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、酯、药学上可接受的盐或前药。该杂环类化合物具有高的P2X3拮抗活性，且具有较好的选择性，毒性较低、代谢稳定性较好、味觉影响较小。